Risk steatosis from imazalil
This standard action is of type: Risks
Traditional risk assessment often uses animal data to evaluate toxicological limit values, such as the acceptable daily intake (ADI). However, in-vitro tests may help to reduce the use of test animals. In the standard action described here such a traditional risk calculation can be compared to a similar calculation based on in-vitro data. For example, a risk calculation of steatosis as health effect and imazalil as chemical substance can be compared to the toxicological hazard characterisation based on in-vitro data from AdipoRed measurements in human liver cells. In-vitro concentrations are assumed to represent internal liver concentrations. A human physiologically based kinetic model for imazalil is used to extrapolate from in-vitro to in-vivo doses.
In this standard action, risk for steatosis from exposure to imazalil is estimated from in-vivo or in-vitro based hazard characterisations.
- Two parameter sets are available:
estimates based on QSAR models only, and
estimates based on QSAR models and in-vitro experiments.
The latter parameter set shows that in the long term concentration levels of imazalil in the liver are stationary.
| Table Group | Name | Repository | Type |
|---|---|---|---|
AdverseOutcomePathwayNetworks |
AOPN-Effects-EffectRelations-181017.xlsx |
Standard Actions/Risk steatosis from imazalil |
Fixed |
Effects |
AOPN-Effects-EffectRelations-181017.xlsx |
Standard Actions/Risk steatosis from imazalil |
Fixed |
DoseResponseData |
BfR-HepaRG-AdipoRed-Single.xlsx |
Standard Actions/Risk steatosis from imazalil |
Fixed |
Concentrations |
ConcentrationsSSD_20190129.zip |
Standard Actions/Risk steatosis from imazalil |
Fixed |
Compounds |
EuroMix Substances Inventory (v8) (PPPs).zip |
Standard Actions/Risk steatosis from imazalil |
Fixed |
PbkModels |
Euromix-Cosmos_Tebby et al ParamB_QSAR_vitro.xlsx |
Standard Actions/Risk steatosis from imazalil |
Fixed |
UnitVariability |
Foods coded in FoodEx1.mdb |
Standard Actions/Risk steatosis from imazalil |
Fixed |
HazardCharacterisations |
HazardCharacterisation Imazalil.xlsx |
Standard Actions/Risk steatosis from imazalil |
Fixed |
Survey |
NL-VCP-RPC 2005-2006 2-6yr.mdb |
Standard Actions/Risk steatosis from imazalil |
Fixed |
Survey |
NL-VCP-RPC 2007-2010 7-69yr.mdb |
Standard Actions/Risk steatosis from imazalil |
Fixed |
Survey |
NL-VCP-RPC 2010-2012 70+yr.mdb |
Standard Actions/Risk steatosis from imazalil |
Fixed |
FoodTranslations |
NL-VCP-RPC Foods.mdb |
Standard Actions/Risk steatosis from imazalil |
Fixed |
Foods |
NL-VCP-RPC Foods.mdb |
Standard Actions/Risk steatosis from imazalil |
Fixed |
EffectRepresentations |
TestSystems-Responses-EffectRepresentations-181026.xlsx |
Standard Actions/Risk steatosis from imazalil |
Fixed |
Responses |
TestSystems-Responses-EffectRepresentations-181026.xlsx |
Standard Actions/Risk steatosis from imazalil |
Fixed |
TestSystems |
TestSystems-Responses-EffectRepresentations-181026.xlsx |
Standard Actions/Risk steatosis from imazalil |
Fixed |